Loading...
Exelixis, Inc.
EXEL•NASDAQ
Healthcare
Biotechnology
$44.39
$-1.21(-2.65%)
Exelixis, Inc. (EXEL) Financial Performance & Income Statement Overview
Review Exelixis, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
18.49%
↑ 18.49%
Operating Income Growth
253.82%
↑ 253.82%
Net Income Growth
150.89%
↑ 150.89%
Operating Cash Flow Growth
110.00%
↑ 110.00%
Operating Margin
33.15%
↑ 33.15%
Gross Margin
96.78%
↑ 96.78%
Net Profit Margin
27.99%
↑ 27.99%
ROE
29.35%
↑ 29.35%
ROIC
31.25%
↑ 31.25%
Exelixis, Inc. (EXEL) Income Statement & Financial Overview
Review Exelixis, Inc.'s (EXEL) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $555.45M | $566.75M | $539.54M | $637.18M |
| Cost of Revenue | $19.17M | $19.96M | $17.33M | $17.67M |
| Gross Profit | $536.27M | $546.79M | $522.21M | $619.51M |
| Gross Profit Ratio | $0.97 | $0.96 | $0.97 | $0.97 |
| R&D Expenses | $212.23M | $249.002M | $222.57M | $211.15M |
| SG&A Expenses | $137.18M | $134.33M | $111.80M | $132.01M |
| Operating Expenses | $349.42M | $383.58M | $386.14M | $343.64M |
| Total Costs & Expenses | $368.59M | $403.55M | $403.47M | $361.30M |
| Interest Income | $19.08M | $21.30M | $18.71M | $17.26M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $7.34M | $7.64M | $7.45M | $7.33M |
| EBITDA | $194.20M | $171.10M | $195.30M | $283.68M |
| EBITDA Ratio | $0.35 | $0.30 | $0.36 | $0.45 |
| Operating Income | $186.86M | $163.21M | $136.07M | $275.87M |
| Operating Income Ratio | $0.34 | $0.29 | $0.25 | $0.43 |
| Other Income/Expenses (Net) | $18.83M | $21.57M | $18.68M | $16.97M |
| Income Before Tax | $205.69M | $184.77M | $154.75M | $292.85M |
| Income Before Tax Ratio | $0.37 | $0.33 | $0.29 | $0.46 |
| Income Tax Expense | $46.07M | $44.91M | $36.78M | $66.73M |
| Net Income | $159.62M | $139.86M | $117.97M | $226.12M |
| Net Income Ratio | $0.29 | $0.25 | $0.22 | $0.35 |
| EPS | $0.57 | $0.48 | $0.41 | $0.78 |
| Diluted EPS | $0.55 | $0.47 | $0.40 | $0.77 |
| Weighted Avg Shares Outstanding | $278.80M | $284.53M | $285.62M | $289.22M |
| Weighted Avg Shares Outstanding (Diluted) | $288.18M | $293.55M | $291.48M | $293.97M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan